Avalyn Pharma Inc. 8K

Avalyn Pharma Inc. announced second quarter 2026 financial results and business updates, including completion of MIST Phase 2b enrollment for AP01, continued advancement of AP02 and AP03 clinical programs, and a cash runway projected into 2029.

Avalyn Pharma Inc. reported its unaudited financial results for the quarter ended June 30, 2026, highlighting completion of global enrollment in its MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis with 398 patients (topline data expected in the second half of 2027), continued enrollment progress in the AURA Phase 2 trial of AP02 in idiopathic pulmonary fibrosis (topline data anticipated in late 2027), and plans to initiate a Phase 1 trial of combination candidate AP03 by the end of 2026; the company also noted acceptance of two AP01-related abstracts for presentation at the September 2026 ERS Congress and disclosed a strong cash position of $413.5 million (including IPO proceeds from May 2026) projected to fund operations into 2029, alongside second quarter 2026 R&D expenses of $24.7 million, G&A expenses of $6.6 million, and a net loss of $28.9 million.

Filing Facts

CIK

1540171

Ticker

AVLN

Form

8K

Source Type

fda

Accession

0001193125-26-345807

Alert Tier

6